United States General Anesthesia Drugs Market Report by Drug Type, Route of Administration, End Use, Application, States and Companies Analysis 2026–2034

United States General Anesthesia Drugs Market Size & Forecast 2026-2034

United States General Anesthesia Drugs Market is projected to grow from USD 1.84 billion in 2025 to USD 2.4 billion in 2034, at a compound annual growth rate of 3.02% during the period 2026-2034. United States General Anesthesia Drugs Market is fueled by the high number of procedures, advanced infrastructure in hospitals, high incidence of chronic diseases, and rise in the demand for complex and long-duration procedures, thereby requiring efficient general anesthesia facilities in hospitals.

United States General Anesthesia Drugs Market Outlook

General anesthesia drugs can be defined as those categories of drugs that create a state of temporary total unconsciousness, painlessness, muscle relaxation, and reflex inhibition during surgical and diagnostic procedures. Therefore, these drugs are normally administered intravenously, inhaled, or in a combination of each other with the aim of keeping the patients unaware and immobile during complex and long surgeries. General anesthesia drugs work by inhibiting the central nervous system, which is responsible for pain perception and consciousness, hence allowing the surgeons to conduct their surgeries safely and effectively. These drugs are critical in major surgeries such as cardiovascular, neurological, orthopedic, and abdominal surgeries.

In the United States, the drugs used in general anesthesia are widely used due to the high number of surgeries performed in the country and the well-equipped health infrastructure. The high rate at which the surgeries are performed, whether elective or immediate, is also a contributing factor to the common use of the drugs. The health facilities in the country are equipped to offer quality services with the help of modern technology and professionals who can assist in the process without any complications. Therefore, the need for pain-free and accurate surgical procedures with the help of the drugs is a contributing factor to the common use of the drugs.

Growth Drivers of the United States General Anesthesia Drugs Market

High and Growing Surgical Procedure Volumes

The United States performs the largest number of surgeries among all nations around the globe. Therefore, the total number of surgeries performed becomes the most important factor for the growth of the general anesthesia drugs market. The increasing number of lifestyle diseases like cardiovascular diseases, cancer, obesity, and orthopedic disorders demands more surgeries. In addition to this, the increasing age of the population also demands more surgeries. Therefore, the older generation also demands more surgeries like joint replacement, cardiovascular, and neurological surgeries, which demand general anesthesia drugs. The well-developed hospital network that provides the necessary services also acts as a driving factor for the growth of the market. As the surgical methods and the complexity of the surgeries are increasing, the demand for general anesthesia drugs is also increasing. The hospitals in the United States where the surgeries are being performed in the highest number are Ochsner LSU Health Shreveport - St. Mary Medical Center, New York-Presbyterian Weill Cornell Medical Center, and University Hospital in Madison, Wisconsin. The three hospitals in the United States performed around 503,058 surgeries in 2023.

Advanced Healthcare Infrastructure and Technology Adoption

The US also has excellent healthcare infrastructure, which in turn helps in the consumption of general anesthesia drugs. The medical facilities available in this country have excellent infrastructure, which helps in the accurate use of general anesthesia drugs. The continuous development and implementation of medical technology enable the effective use of new and relatively more recent anesthesia drugs with a better safety level. In addition to that, the country also provides access to highly qualified and supportive medical professionals. All these factors strengthen the overall consumption pattern of general anesthesia drugs. The supportive environment also augments the current level of consumption of general anesthesia drugs and helps in the development of the overall market. Announced on Feb 2026, GE HealthCare’s innovative medical technology solution, Allia™ Moveo, has received US FDA 510(k) Clearance and CE Marking. The solution will provide greater mobility and precision in interventional rooms. At the Radiological Society of North America’s 2025 Annual Meeting, the innovative solution, Allia, was launched for the US medical community. The solution will be employed for cardiovascular, vascular, non-vascular, interventional, surgical, and supportive procedures. The minimally invasive C-arm system is equipped with a user-friendly interface and AI solutions for greater efficiency and flexibility in space-restricted settings.

Rising Demand for Complex and Elective Surgeries

Another significant factor that has contributed to the growth of the US general anesthesia drug market is the rising demand for complex and elective surgeries. The rise in the number of elective surgeries such as cosmetic, bariatric, and orthopedic joint replacement surgeries has significantly fueled the demand for general anesthesia. These factors, along with the advancements in medical diagnostics, aid in the early detection of diseases, thus providing a boost to the healthcare industry. The fact that the citizens of the US are seeking improved, pain-free, and better overall experiences with regard to general anesthesia can be realized by understanding the capacity within which insurance or other reimbursement mechanisms are available to support the healthcare industry in the US. June 2025, UC Davis Health had a ribbon-cutting ceremony to mark the opening of its new outpatient surgery center, 48X Complex, which is now one of the largest in the nation. The ribbon-cutting ceremony was attended by representatives of UC Davis Health, the community, as well as those from the surrounding neighborhood of Oak Park.

Challenges of the United States General Anesthesia Drugs Market

Drug Safety Concerns and Regulatory Scrutiny

The safety issues related to the use of general anesthesia drugs are an emerging issue in the U.S. industry. The following issues have raised the overall level of concern related to the use of general anesthesia drugs: adverse drug reactions, post-operative nausea, cognitive impairments in the elderly, and comorbid conditions. As a result of the overall increase in concerns related to the safety of general anesthesia drugs, the regulatory agencies have been reviewing these drugs rather strictly. The regulatory policies have raised the overall costs incurred by the drug companies during the development of their products. The patients are becoming more aware of the risks associated with the use of anesthesia drugs. This may also affect their treatment preferences to some extent. The overall concerns related to the impact and risks associated with the use of such drugs have encouraged investments in this area.

Cost Pressures and Availability of Alternatives

The market is also experiencing challenges associated with cost restrictions in the form of healthcare cost management services, which are impacting the growth of the U.S. general anesthesia drug market. With the growing need for value-based care services, hospitals and other institutions are becoming more focused on optimizing the services and costs. Additionally, anesthesia areas such as local anesthesia and sedation are also providing alternatives in many instances. The effect of generics has also introduced a significant element in the form of pricing pressure on the U.S. general anesthesia drug market. The rising costs of these services are becoming a significant challenge to the growth of the general anesthesia drug market in the country. As such, the market is also experiencing challenges associated with budget restrictions, which are impacting the growth of the market.

United States Propofol Drugs Market

The United States propofol market size for drugs is a crucial part of general anesthetics and procedural sedation/anesthetics owing to their rapid onset of action, short duration of action, and recovery characteristics. Propofol is widely used for the maintenance of anesthesia in surgical procedures and sedation in diagnostic or intensive care procedures. Propofol has been found to cause smooth recovery for patients, making it a highly sought-after drug among anesthetists. The large number of surgical procedures, popularity of minimally invasive surgical procedures, and familiarity with its use lead to a constant demand for this anesthetic drug. Despite the market’s dependence on reduced price pressure with generic forms of this drug and risks associated with the supply chain, it is a crucial anesthetic agent. The constant support for the drug usage in various medical institutions across the country is ensured by the use of advanced monitoring devices and training of professional anesthetists.

United States Remifentanil Drugs Market

The ultra-short-acting opioid nature of the drug, combined with the ability to control it well during anesthesia, fuels the market growth of remifentanil drugs in the United States. Remifentanil is used as an active pharmaceutical ingredient and is widely used as an adjunct to general anesthesia in complex and high-risk surgeries like cardiovascular, neurological, and major abdominal surgeries. The drug has a rapid metabolism rate that assists anesthesiologists in controlling analgesic depth effectively and provides rapid postoperative recovery, especially in critical care and fast-track surgical procedures. The demand for highly controlled anesthesia management in specialized surgeries fuels the market growth. Remifentanil drugs are mainly used in hospital-based operating rooms with advanced anesthesia monitoring and trained staff. The regulatory challenges and issues associated with opioids affect the prescribing practice; however, the unique clinical advantages will continue to sustain remifentanil in advanced anesthesia management in the United States.

United States Desflurane Drugs Market

The market for desflurane drugs in the United States is characterized by favorable market conditions, driven by the high demand for inhalational anesthetic agents that have rapid induction with extremely rapid recovery profiles. Desflurane is commonly used in surgeries that are long and complex, involving rapid recovery from the anesthetic effects of anesthesia, which can be very beneficial for obese and geriatric patients. The United States hospital setting favors the use of desflurane in surgeries that require precise control of anesthesia depth with minimal postoperative sedation. The availability of advanced anesthesia delivery systems and experienced anesthesiology professionals has made it easier to utilize desflurane safely. Concerns about environmental effects and higher costs have impacted the desflurane market. The use of desflurane remains steady in the tertiary care and academic setting, where the performance and recovery profiles of desflurane are important. The need for surgeries in the routine setting has continued to support the use of desflurane in the specialized hospital setting.

United States Intravenous General Anesthesia Drugs Market

The US, or United States, intravenous general anesthesia drug market is experiencing growth, primarily due to the rise in the preference for total intravenous anesthesia (TIVA) in certain surgical and diagnostic procedures. This can be attributed to the fact that intravenous anesthetics assist in managing the dosage, maintaining a constant level of anesthesia, as well as preventing post-operative nausea. IV anesthetics are commonly used in outpatient surgical centers, as well as in ensuring effective recovery, primarily due to the fact that they can be easily tracked using the latest technological advancements, further increasing preference in US-based facilities and organizations. This is attributed to the fact that intravenous anesthetics can work effectively in a number of surgical procedures, thus increasing patient satisfaction through effective recovery, while also improving outcomes, especially when compared to the preference for other general anesthetics, such as inhalation anesthetics.

United States General Anesthesia Drugs Market in Hospitals

The end-user segment that comprises hospitals represents the largest market share for general anesthesia drugs used in the country because of the performance of complex and risky surgical procedures that require longer periods. The operating rooms are equipped with highly advanced and sophisticated equipment necessary for the administration of general anesthesia drugs. Furthermore, the rising number of surgical procedures due to chronic diseases, trauma, and the rising number of the elderly in the country continues to fuel the market. Additionally, hospitals are specialized centers for cardiac surgeries, neurosurgical procedures, and transplantations that specifically require general anesthesia. Although cost and compliance are critical in the purchase of general anesthesia drugs, efficacy and safety are the key factors in this segment.

California General Anesthesia Drugs Market

The market share of California's general anesthesia drugs is one of the largest in the United States, owing to factors such as the well-developed healthcare infrastructure, large population base, and high number of surgeries that require general anesthesia drugs. California has a number of specialized hospitals that are classified as Class A or Tertiary care hospitals and perform surgeries that require general anesthesia. In addition to this, there are a number of ambulatory surgical centers that are established to meet the demands of customers who require general anesthesia drugs for their surgeries. Chronic problems that are prevalent in the state, in addition to the aging population that requires general anesthesia drugs for surgeries such as orthopedic, cardiovascular, neurological, and cosmetic surgeries, enhance the well-developed demand for general anesthesia drugs in California. In addition to this, California is the first life sciences innovator in the United States, which enhances the demand for general anesthesia drugs. Owing to the challenges posed by the costs and regulatory requirements that affect the selection of suppliers for California's general anesthesia drugs, the process enhances growth for the California general anesthesia drugs market.

New York General Anesthesia Drugs Market

The general anesthesia drugs market in the state of New York can be said to be a market with a high density of surgeries and a high concentration of large hospitals in the state. Therefore, ensuring that the high-density areas in the state are locations for a large number of complex, emergency, and elective surgeries that require general anesthesia drugs for the effective administration of medical care among the population in the state. In addition, the high patient diversity, prevalence of chronic diseases, and the aging population of patients are some of the factors that are contributing to the demand for general anesthesia drugs in the state. Therefore, with the high patient safety focus, outcomes, and efficiency-oriented model of the medical and healthcare sector in the state of New York, the general anesthesia drugs market has continued to enjoy a substantial market base in the country.

Washington General Anesthesia Drugs Market

The Washington general anesthesia market is fueled by an existing healthcare system and an increasing need for surgical procedures. The hospitals and surgical centers in the Washington region provide a range of surgical services, such as orthopedic, general, and specialty surgeries, which require general anesthesia. The factors that drive the Washington general anesthesia market include the large aging population in the state of Washington, increased access to healthcare services, and increased awareness of new procedures. Washington is dedicated to providing the highest level of care and ensuring that it uses current technology. It has some of the most prestigious healthcare facilities and specialty surgical centers that use certified professionals. It retains the focus on cost containment; therefore, the key factor that determines the market is medical necessity. The Washington market is a good market for stable growth.

Arizona General Anesthesia Drugs Market

The Arizona general anesthesia drugs market is growing at a steady pace due to the rising demand for surgeries and the fast development of healthcare facilities. Firstly, the older population in Arizona leads to surgeries such as joint replacement, cardiovascular surgery, and general surgery, among others, which require general anesthesia. Secondly, the rising development of healthcare facilities, such as private hospitals and clinics, leads to a steady rise in the Arizona general anesthesia drugs market. In addition, healthcare facilities in Arizona are performing minimally invasive procedures, thus leading to a steady rise in the overall Arizona market. Moreover, the population of Arizona is rising, thus leading to a steady demand for anesthesia drugs. Taking into consideration the above factors, it is evident that the Arizona general anesthesia drugs market will grow. Despite the uneven distribution of resources, the steady growth of healthcare facilities will lead to overall growth.

Market Segmentation

Drug Type

• Sevoflurane
• Propofol
• Dexmedetomidine
• Remifentanil
• Desflurane
• Midazolam
• Others

Route of Administration

• Intravenous
• Inhaled

End Use

• Hospitals
• Ambulatory Surgical Centers
• Others

Application

• Heart Surgeries
• Cancer
• General Surgery
• Knee and hip replacements
• Other

Top States 

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis:

• Baxter International Inc.
• AstraZeneca
• AbbVie Inc.
• B. Braun Melsungen AG
• Fresenius SE & Co. KgaA
• Pfizer
• Hospira Inc.
• Aspen Pharmacare Holdings Limited
• Hikama Pharmaceuticals plc
• Abbott Laboratories

Report Details: